Privia Health Group, Inc. (PRVA) Research
Privia Health Group, Inc. functions as a national entity focused on empowering physicians throughout the United States. It partners with medical groups, health plans, and health systems, with the primary objective of optimizing physician practices, enhancing patient experiences, and appropriately compensating clinicians for care delivered both virtually and in person. To achieve this, Privia offers a comprehensive suite of services. These include technology and population health tools designed to streamline independent providers' workflows; a Management Services Organization (MSO) that alleviates administrative tasks, freeing providers to focus on clinical care; a single-TIN medical group, which bolsters payer negotiations, facilitates clinical integration, and aligns financial incentives; an Accountable Care Organization (ACO) designed to engage patients, reduce inefficient utilization, and improve care coordination and patient quality metrics, thereby advancing value-based care; and a network connecting providers with new patient populations and enabling custom contracts with purchasers and payers. Founded in 2007, the company's headquarters are located in Arlington, Virginia. Privia Health Group, Inc. was formerly a subsidiary of Brighton Health Group Holdings, LLC.
Market snapshot
- Symbol
- PRVA
- Price
- $23.67
- Day change
- +1.11%
- Market cap
- $3.0B
- P/E ratio
- 135.03x
- 52-week range
- 18.77-26.51
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Next earnings
- in 2 months
- Analyst price target
- $30.00
Peer companies
Recent insider activity
- SOISTMAN FRANCIS S JR — A-Award (8463 shares) on 2026-05-20
- BERBERIAN LANCE — A-Award (8463 shares) on 2026-05-20
- COCOZZA NANCY G — A-Award (8463 shares) on 2026-05-20
- Kimmet Pamela O — A-Award (8463 shares) on 2026-05-20
- McCarthy Thomas A — A-Award (8463 shares) on 2026-05-20
Open Privia Health Group, Inc. (PRVA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.